LONDON, April 29, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 May, 2014 its second quarter and half year financial results for the period ending 31 March, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).
Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
CONTACT: Enquiries: GW Pharmaceuticals plc (Today) +44 20 3727 1000 Justin Gover, CEO +44 1980 557000 Stephen Schultz, VP Investor Relations + 1 401 500 6570 FTI Consulting Ben Atwell / Simon Conway / John Dineen (European media enquiries) + 44 20 3727 1000 Robert Stanislaro (US media enquiries) +1 212 850 5657 Trout Group, LLC (US investor relations) Todd James / Chad Rubin +1 646 378 2900Source:GW Pharmaceuticals plc